NCT05166668 is a NA clinical trial of Letrozole 2.5mg tablet in Ovarian Stimulation, sponsored by Menoufia University.

Who is sponsoring NCT05166668?

NCT05166668 is sponsored by Menoufia University.

What drugs are being tested in NCT05166668?

Interventions in NCT05166668: Letrozole 2.5mg tablet.

What condition does NCT05166668 study?

NCT05166668 studies Ovarian Stimulation.

Is NCT05166668 still recruiting?

NCT05166668 is currently completed. Last updated 12 February 2025.

Last reviewed 2025-02-12 · How we verify

NCT05166668

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle

Completed NA Last updated 12 February 2025

What this trial tests

NA trial testing Letrozole 2.5mg tablet in Ovarian Stimulation in 200 participants. Completed in 10 February 2025.

Timeline

1 November 2021

Primary endpoint
10 February 2025

10 February 2025

Quick facts

Lead sponsor	Menoufia University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	1 November 2021
Primary completion	10 February 2025
Estimated completion	10 February 2025
Sites	1 location across Egypt

Drugs / interventions tested

Letrozole 2.5mg tablet — full drug profile →

Conditions studied

Ovarian Stimulation — all drugs for Ovarian Stimulation →

Sponsor

Menoufia University

Who can join

Adults 40 to 44, female only, with Ovarian Stimulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study To compare the clinical and laboratory outcomes of two ovarian stimulation protocols (standard GnRH antagonist protocol and aromatase inhibitor/ antagonist protocol) in women (40-44) years undergoing ICSI cycle.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Ovarian Stimulation

Currently open trials in the same condition.

NCT06175832 — PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study · Phase 4 · recruiting
NCT06572930 — Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation · recruiting

Other Menoufia University trials

Trials by the same sponsor.

NCT07522671 — Clinical Performance of 3D-Printed Resin and Zirconia Implant Restorations · NA · recruiting
NCT07516236 — Dynamic SvO2 in Predicting Fluid Responsiveness in Septic Shock · not yet recruiting
NCT07485517 — Deep Versus Moderate Neuromuscular Blocking · NA · recruiting
NCT07506044 — Dexmedetomidine as an Adjuvant During Dural Puncture Epidural · NA · recruiting
NCT07322471 — Efficacy and Safety of Flexible Ureteroscopy Versus Percutaneous Nephrolithotomy in Management of Staghorn Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05166668 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Menoufia University
Last refreshed: 12 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05166668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing